Chemotherapy for androgenindependent prostate cancer: Myth or reality-Reference-Cited by-同舟云学术

Chemotherapy for androgenindependent prostate cancer: Myth or reality

Published:2000-10 Issue:5 Volume:2 Page:394-401
ISSN:1523-3790
Container-title:Current Oncology Reports
language:en
Short-container-title:Curr Oncol Rep

Author:

Kelly Wm. Kevin,Slovin Susan F.

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/content/pdf/10.1007/s11912-000-0058-0.pdf

Reference40 articles.

1. Newling DWW: Orchiectomy versus zoladex and flutamide in the treatment of newly diagnosed metastatic prostate cancer.Cancer 72:3793–3798, 1993.

2. Kyprianou N, English HF, Issacs JT: Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 1990, 50:3748–3753.

3. Agus DB, Cordon-Cardo C, Fox W, et al.: Prostate cancer cell cycle regulators: response to androgen withdrawal and androgen independence. J Natl Cancer Inst 1999, 91:1869–1876. This human model of prostate cancer suggests that androgen withdrawal results in cell cycle arrest rather than apoptosis, and that release from the cell cycle arrest results in androgenindependent disease.

4. Yagoda A, Petrylak DP: Cytotoxic chemotherapy for advanced hormone resistant prostate cancer. Cancer 1993, 71(suppl 3):1098–1099.

5. Moore MJ, Osoba D, Murphy D, et al.: Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol 1994, 12:689–694, 1994.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pre-clinical evaluation of 1-nitroacridine derived chemotherapeutic agent that has preferential cytotoxic activity towards prostate cancer;Cancer Biology & Therapy;2007-10

2. Strategies for Prostate Cancer Gene Therapy;American Journal of Cancer;2004

3. Randomized, Multicenter, Phase II Trial of Two Multicomponent Regimens in Androgen-Independent Prostate Cancer;Journal of Clinical Oncology;2003-03-01